The opinions expressed herein are the guest's alone and have not been reviewed by a WebMD physician. If you have questions about your health, you should consult your personal physician. This event is ...

Two interesting trials in ovarian cancer were presented yesterday with impressive results and a surprising prediction about their futures.Avastin (bevacizumab) and olaparib, a PARP inhibitor, were ...

A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the U.S.

After two days of testimony, an FDA advisory panel has decided -- again -- that Avastin should no longer be approved to treat metastatic breast cancer. The panel listened to patients who said the drug ...

(Reuters) - Counterfeit versions of Roche's multi-billion cancer drug Avastin have been distributed in the United States, the Swiss drugmaker and its U.S. biotech unit Genentech said on Tuesday. Roche ...

CHICAGO--(BUSINESS WIRE)-- Genentech, Inc., a wholly owned member of the Roche Group, (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a Phase III study of Avastin® (bevacizumab) that showed ...

Avastin is an angiogenesis inhibitor, meaning it cuts off the independent blood supply that a tumor develops to feed and oxygenate itself. A molecularly targeted therapy, Avastin neutralizes vascular ...

New findings have reignited hope and purpose for Avastin, says expert. January 25, 2011— -- Taking Avastin before breast cancer surgery could significantly shrink tumors and reduce the chance of ...

The Food and Drug Administration Thursday started the process of removing approval for the use of a common cancer drug to treat breast cancer. The FDA said the drug, Avastin, isn’t effective enough, ...

ZURICH, April 22 (Reuters) - Cancer drug Avastin -- a key Genentech asset now wholly owned by Roche Holding AG -- has failed in a major study to prevent the recurrence of colon cancer in patients who ...

The evidence for avastin versus lucentis is weak for one very simple reason: the company refused to license it. Whether this was because of cock-up or conspiracy does not matter. Cock-up in that Roche ...